Ronald Vender

4.5k total citations · 1 hit paper
139 papers, 2.7k citations indexed

About

Ronald Vender is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Ronald Vender has authored 139 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Immunology, 77 papers in Dermatology and 29 papers in Pathology and Forensic Medicine. Recurrent topics in Ronald Vender's work include Psoriasis: Treatment and Pathogenesis (94 papers), Dermatology and Skin Diseases (61 papers) and Autoimmune Bullous Skin Diseases (28 papers). Ronald Vender is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (94 papers), Dermatology and Skin Diseases (61 papers) and Autoimmune Bullous Skin Diseases (28 papers). Ronald Vender collaborates with scholars based in Canada, United States and Germany. Ronald Vender's co-authors include Charles Lynde, Marc Bourcier, Yves Poulin, Denis Sasseville, Francis Murphy, Channy Muhn, Sam Khalil, Kim Papp, Andrew Blauvelt and Andreas Pinter and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Ronald Vender

135 papers receiving 2.6k citations

Hit Papers

Bimekizumab efficacy and ... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    2021 170 citations Peter Foley, Andreas Pinter et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ronald Vender 1.8k 1.4k 486 437 388 139 2.7k
F. Vanaclocha 1.7k 0.9× 1.3k 0.9× 377 0.8× 460 1.1× 458 1.2× 130 2.7k
Peter van de Kerkhof 2.3k 1.3× 1.5k 1.1× 296 0.6× 407 0.9× 473 1.2× 48 3.1k
J.M. Carrascosa 2.1k 1.1× 1.5k 1.0× 317 0.7× 383 0.9× 455 1.2× 211 3.0k
Paul Klekotka 2.4k 1.3× 939 0.7× 387 0.8× 272 0.6× 311 0.8× 45 3.2k
Jerry Bagel 2.1k 1.2× 1.5k 1.1× 188 0.4× 367 0.8× 473 1.2× 125 2.7k
Sandra Philipp 2.6k 1.4× 1.6k 1.1× 341 0.7× 338 0.8× 462 1.2× 79 3.5k
I. García‐Doval 1.2k 0.7× 1.1k 0.8× 586 1.2× 445 1.0× 516 1.3× 165 2.8k
Michel Le Maître 2.0k 1.1× 1.2k 0.8× 271 0.6× 290 0.7× 703 1.8× 43 2.6k
R.J.G. Chalmers 1.5k 0.8× 1.1k 0.8× 468 1.0× 443 1.0× 691 1.8× 80 3.0k
Robert Matheson 2.0k 1.1× 1.2k 0.8× 382 0.8× 299 0.7× 499 1.3× 20 2.7k

Countries citing papers authored by Ronald Vender

Since Specialization
Citations

This map shows the geographic impact of Ronald Vender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Vender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Vender more than expected).

Fields of papers citing papers by Ronald Vender

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Vender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Vender. The network helps show where Ronald Vender may publish in the future.

Co-authorship network of co-authors of Ronald Vender

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Vender. A scholar is included among the top collaborators of Ronald Vender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Vender. Ronald Vender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prajapati, Vimal H., Charles Lynde, Melinda Gooderham, et al.. (2024). Considerations for defining and diagnosing generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology. 39(3). 487–497. 4 indexed citations
2.
Drakos, Anastasia, Tiago Torres, & Ronald Vender. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics. 16(1). 111–111. 15 indexed citations
3.
Torres, Tiago, et al.. (2024). A systematic review of recent randomized controlled trials for palmoplantar pustulosis. Journal of Dermatological Treatment. 35(1). 2414048–2414048.
4.
Vender, Ronald, et al.. (2024). Predicting psoriasis severity using machine learning: a systematic review. Clinical and Experimental Dermatology. 50(3). 520–528. 3 indexed citations
5.
Georgakopoulos, Jorge R., et al.. (2024). Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study. Journal of the American Academy of Dermatology. 91(5). 936–939. 5 indexed citations
6.
Egeberg, Alexander, Andreas Pinter, Ronald Vender, et al.. (2023). 42592 Baseline Characteristics and Interim Month 12 mNAPSI Results in Patients with Moderate-to- Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Journal of the American Academy of Dermatology. 89(3). AB127–AB127. 1 indexed citations
7.
Vender, Ronald, et al.. (2023). Plaque psoriasis and morphea in a patient on ustekinumab: A case report. SHILAP Revista de lepidopterología. 11. 2050313X231164207–2050313X231164207. 2 indexed citations
8.
Reich, Adam, Andreas Pinter, Julia‐Tatjana Maul, et al.. (2023). Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology. 37(9). 1825–1840. 6 indexed citations
9.
10.
Papp, Kim, Barbara Melosky, Sandeep Sehdev, et al.. (2023). Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy. 13(4). 867–889. 10 indexed citations
11.
Bissonnette, Robert, Andreas Pinter, Laura K. Ferris, et al.. (2023). 78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1. Journal of Investigative Dermatology. 143(11). S345–S345. 3 indexed citations
12.
13.
Egeberg, Alexander, Lars Erik Kristensen, Ronald Vender, et al.. (2022). Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3. Acta Dermato Venereologica. 102. adv00787–adv00787. 7 indexed citations
14.
Vender, Ronald, et al.. (2021). A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic. Journal of Cutaneous Medicine and Surgery. 25(3). 298–302. 3 indexed citations
15.
Blauvelt, Andrew, C. Leonardi, Boni E. Elewski, et al.. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184(6). 1047–1058. 73 indexed citations
16.
Fahim, Christine, Marc Bourcier, Steven J. Glassman, et al.. (2019). Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. Journal of Cutaneous Medicine and Surgery. 23(3). 282–288. 2 indexed citations
17.
Cohen, Arnon D., Jashin J. Wu, L. Puig, et al.. (2017). Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology. 177(6). 1495–1502. 33 indexed citations
18.
Vender, Ronald, et al.. (2016). Psoronychomycosis. Journal of Cutaneous Medicine and Surgery. 20(3). 279–280. 5 indexed citations
19.
Vender, Ronald, et al.. (2015). Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon. Journal of Cutaneous Medicine and Surgery. 19(3). 320–322. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Vanaclocha Breakdown of academic impact, for papers by Peter van de Kerkhof Breakdown of academic impact, for papers by J.M. Carrascosa Breakdown of academic impact, for papers by Paul Klekotka Breakdown of academic impact, for papers by Jerry Bagel Breakdown of academic impact, for papers by Sandra Philipp Breakdown of academic impact, for papers by I. García‐Doval Breakdown of academic impact, for papers by Michel Le Maître Breakdown of academic impact, for papers by R.J.G. Chalmers Breakdown of academic impact, for papers by Robert Matheson
Rankless by CCL
2026